UniPharma Co., Ltd. (TPEX:6621)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.35
-0.40 (-3.14%)
Apr 20, 2026, 1:23 PM CST

UniPharma Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
88.4493.46103.22128.11105.39
Revenue Growth (YoY)
-5.36%-9.46%-19.43%21.56%-23.98%
Cost of Revenue
41.2244.7552.2153.4946.06
Gross Profit
47.2248.7151.0274.6259.33
Selling, General & Admin
68.5262.9660.4969.1866.5
Research & Development
22.8316.5717.8326.3233.05
Operating Expenses
91.3579.5378.3295.599.55
Operating Income
-44.13-30.82-27.31-20.88-40.22
Interest Expense
-0.1-0.11-0.01-0.04-0.1
Interest & Investment Income
2.081.951.971.261.24
Currency Exchange Gain (Loss)
-0.831.15-0.050.97-0.21
Other Non Operating Income (Expenses)
2.443.063.590.961.28
EBT Excluding Unusual Items
-40.53-24.78-21.81-17.74-38.02
Gain (Loss) on Sale of Assets
-0.01-0.04-10.71-
Asset Writedown
-----36.43
Other Unusual Items
----0.04
Pretax Income
-40.54-24.82-21.81-7.03-74.41
Earnings From Continuing Operations
-40.54-24.82-21.81-7.03-74.41
Minority Interest in Earnings
---0.58-
Net Income
-40.54-24.82-21.81-6.45-74.41
Net Income to Common
-40.54-24.82-21.81-6.45-74.41
Shares Outstanding (Basic)
3636363535
Shares Outstanding (Diluted)
3636363535
Shares Change (YoY)
--0.04%0.81%-
EPS (Basic)
-1.14-0.70-0.61-0.18-2.11
EPS (Diluted)
-1.14-0.70-0.61-0.18-2.11
Free Cash Flow
-37.98-15.113.92-32.09-13.54
Free Cash Flow Per Share
-1.07-0.430.11-0.90-0.39
Gross Margin
53.39%52.12%49.42%58.25%56.29%
Operating Margin
-49.89%-32.98%-26.45%-16.30%-38.16%
Profit Margin
-45.84%-26.56%-21.13%-5.03%-70.60%
Free Cash Flow Margin
-42.94%-16.17%3.80%-25.05%-12.85%
EBITDA
-40.89-27.49-24.99-18.8-34.99
EBITDA Margin
-46.24%-29.42%-24.21%-14.68%-33.20%
D&A For EBITDA
3.233.332.322.075.23
EBIT
-44.13-30.82-27.31-20.88-40.22
EBIT Margin
-49.89%-32.98%-26.45%-16.30%-38.16%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.